FDA Funding for Fiscal Year 2012 Approved

Last week, we provided an update regarding the Super Committee’s struggle to agree to and submit recommendations for deficit reduction by their deadline of Wednesday, November 23.  It is important to note that at the same time the Super Committee is deliberating, Congress continues to consider and approve funding recommendations for the current fiscal year, which began October 1 and runs through September 30, 2012.  Late approval of annual appropriations has become a pattern in recent years.  What follows is the latest news surrounding Fiscal Year (FY) 2012 funding negotiations and anticipated next steps.

On November 14, a Conference Committee consisting of members of the House and Senate reached a compromise agreement on the first of several anticipated spending bills for Fiscal Year (FY 2012).  On November 17, the House and Senate approved this so-called “minibus” bill – a package of three of the twelve total annual appropriations bills bundled together – which includes a $50 million increase for the Food and Drug Administration (FDA) over FY 2011.  The president signed this legislation today, November 18.

Recognizing the urgent need for breakthrough therapies for Parkinson’s disease, PAN supports robust funding for the FDA and is a member of the Alliance for a Stronger FDA, a coalition of more than 185 nonprofit and industry groups working to increase annual appropriations for the FDA.  Earlier this month, PAN sent a letter to the Conference Committee members, encouraging them to increase funding for the agency.
 
The bill approved yesterday also includes an extension of the current Continuing Resolution (CR), which was scheduled to expire at midnight tonight.  Extension of the CR through December 16 affords Congress additional time to take up the remaining FY 2012 spending bills, including those regarding funding for the National Institutes of Health and the Department of Defense.  We will provide additional updates as the process moves forward.